ALLMedicine™ Angioedema Center

Aug 3rd, 2020 - Chronic urticaria (CU), daily wheals or angioedema that last more than 6 weeks, is a common skin disease; CU is classified as spontaneous (no specific eliciting factor involved) or inducible (specific eliciting factor involved). Recent EAACI guide...

Aug 2nd, 2020 - Mucosal angioedema of the face, lips, tongue, and throat is a well-recognized adverse reaction to angiotensin-converting enzyme (ACE) inhibitors that is experienced by a minority of patients. Rarely, this angioedema can involve the small bowel, an...

Jul 27th, 2020 - Coronavirus disease 2019-associated urticaria with angioedema in a morbidly obese man successfully treated with glucocorticoids.|2020|Lockey RF,Hudey SN,|

Jul 25th, 2020 - Review 4 patients who presented with presumed lisinopril-induced angioedema and received C1 esterase inhibitor (C1-INH). Four patients received C1-INH for presumed lisinopril-induced angioedema. In all cases, angioedema was attributed to lisinopri...

Jul 22nd, 2020 - Abdominal pain is one of the most common conditions leading people to the emergency department. An uncommon but well described cause of abdominal pain is angioedema of the gastrointestinal tract due to recurrent angioedema without wheals. Abdomina...

Jan 10th, 2018 - Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. I...

Feb 25th, 2015 - This guidance for the management of patients with chronic urticaria and angioedema has been prepared by the Standards of Care Committee of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well ...

Apr 30th, 2014 - Theworkgroup was formed by the JTFPP to develop a practiceparameter to address the diagnosis and treatment of urticaria withor without angioedema. The chair, Jonathan Bernstein, MD,invited workgroup members to participate in the parameterdevelopme.

Apr 15th, 2014 - Despite its relatively common occurrence and life-threatening potential, the management of angioedema in the emergency department (ED) is lacking in terms of a structured approach. It is paramount to distinguish the different etiologies of angioed...

Jun 3rd, 2013 - These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council ...

Aug 3rd, 2020 - Chronic urticaria (CU), daily wheals or angioedema that last more than 6 weeks, is a common skin disease; CU is classified as spontaneous (no specific eliciting factor involved) or inducible (specific eliciting factor involved). Recent EAACI guide...

Aug 2nd, 2020 - Mucosal angioedema of the face, lips, tongue, and throat is a well-recognized adverse reaction to angiotensin-converting enzyme (ACE) inhibitors that is experienced by a minority of patients. Rarely, this angioedema can involve the small bowel, an...

Jul 31st, 2020 - Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urt...

Jul 27th, 2020 - Coronavirus disease 2019-associated urticaria with angioedema in a morbidly obese man successfully treated with glucocorticoids.|2020|Lockey RF,Hudey SN,|

Jul 26th, 2020 - Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or pl...

Dec 5th, 2019 - Discussion The standard therapy for ACEI-inducedangioedema continues to be airway management and discontinuation of medication. However, life-threatening progression of symptoms have led to the use of off-label therapies, including FFP and bradyki.

Nov 30th, 2018 - Action Points Patients with type I or type II hereditary angioedema (HAE) suffer from regular, unpredictable and life-disrupting attacks, and patients are in need of better drugs to control this lifelong disabling condition. Patients whose HAE is ...

Nov 27th, 2018 - Prophylactic treatment with lanadelumab (Takhzyro) prevented hereditary angioedema attacks and led to a clinically-meaningful impact on quality of life, according to the pivotal HELP trial that led to recent FDA approval. The monoclonal antibody c...

Aug 24th, 2018 - WASHINGTON -- A monoclonal antibody drug for hereditary angioedema (HAE) won FDA approval late Thursday, making it the sixth agent to reach the U.S. market for the rare genetic disorder. Lanadelumab (Takhzyro), made by Shire, was approved for prev...

The U.S. Food and Drug Administration today approved Takhzyro (lanadelumab), the first monoclonal antibody approved in the U.S. to treat patients 12 years and older with types I and II hereditary angioedema (HAE).